This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Global BioDiagnostics Receives Wellcome Trust Support For Development Of New TB Diagnostic

CHESHIRE, England, March 6, 2013 /PRNewswire/ --

A  UK  company has received a £2.6m ( $4.3m) Strategic Translation Award from the Wellcome Trust to progress its development of a new, rapid point-of-care test for the  diagnosis of tuberculosis , one of the world ' s biggest killers.

Global BioDiagnostics (GBD), based at Sci-Tech Daresbury, Cheshire, UK, and Texas, USA, has received the Wellcome Trust money after completing a proof of concept study of a new technique for the diagnosis of tuberculosis.

The test can detect the bacterium that causes TB in as little as 10 minutes. It is based on technology developed at Texas A&M and Stanford and recently described in Nature Chemistry.

The ultimate goal is to develop an accessible, affordable test that can be used at the point of care level in communities across the developing world.

A benchmark evaluation study undertaken in the US and Peru using fresh sputum from suspected TB patients has proven feasibility of the technique for the rapid diagnosis of TB.

Michael T. Norman, CEO of Global BioDiagnostics, said: "This new funding will support refinements of the assay technology and further product development work culminating in field trials of the diagnostic test and CE registration.

"We hope to develop a test that will enable accurate diagnosis at an earlier stage of infection, while requiring little by way of clinical or technical skill, in a matter of minutes and at a fraction of current costs."

The new diagnostic test uses technology developed by Dr Jeffrey D Cirillo of Texas A&M Health Science Center College of Medicine, near Houston, and Dr Jianghong Rao of Stanford University, California.    

The basic research has taken more than five years and has been funded through an on-going £3m-plus ( $5m-plus) grant from the Bill and Melinda Gates Foundation to Texas A&M.

The technology utilises novel chemical substrates that generate a fluorescent signal when they come into contact with an enzyme produced by the bacterium causing TB. This technology is called Reporter Enzyme Fluorescence, or REF.  The fluorescent signal is easily detected by simple, low cost, portable fluorometers that are commercially available.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs